New Case Study Published: Investigating The Formulation of Cytocaf® Materials as Polymeric Inks for Bioprinting

New Case Study Published: Investigating The Formulation of Cytocaf® Materials as Polymeric Inks for Bioprinting

We’re delighted to share a new case study from the Henry Royce Institute highlighting our collaboration with CPI and the Royce to develop next-generation animal-free bioinks for 3D bioprinting, funded by the Royce Industrial Collaboration Programme (ICP).

The project explored how MarraBios engineered Cytocaf® proteins can be integrated into sustainable synthetic hydrogel systems to create printable, biologically active materials for advanced cell culture and tissue engineering applications.

Key outcomes included:
– Production of Cytocaf® polymers for 3D stem cell culture
– Successful incorporation of Cytocaf® proteins into printable hydrogel formulations
– Identification of promising Cytocaf®-functionalised dextran bioinks
– Demonstration of favourable printing characteristics and initial biocompatibility with human cells
– Progress towards more human-relevant osteochondral tissue models for osteoarthritis research

Importantly, this work supports the UK’s 3Rs agenda (Replace, Reduce, Refine) by reducing reliance on animal-derived biomaterials and enabling more predictive human-relevant models for drug discovery and regenerative medicine.

As we continue to expand the capabilities of the Cytocaf® platform, we’re excited about the opportunities this creates for advanced disease models, tissue engineering and next-generation biomaterials.

Read the full case study here: https://www.royce.ac.uk/research/impact/investigating-the-formulation-of-caf1-based-materials-as-polymeric-inks-for-bioprinting/

If you’re interested in how Cytocaf® proteins can improve your 3D cell culture workflows, please get in touch: info@marrabio.com